

I hereby certify that this correspondence and any paper referred to as being attached or enclosed is being mailed via "First Class Mail" of the United States Postal Service on the date shown below in an envelope addressed to the Assistant Commissioner for Patents, U.S. Patent & Trademark Office, Washington, D.C. 20231



By Karyn F. Massie
Karyn F. Massie

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT APPLICATION

Inventor(s): Fang, et al.

Appl. No.: 09/ 910,483

Series Code ↑

Serial No. ↑

Filed: July 19, 2001

Hon. Commissioner of Patents
Washington, D.C. 20231

Group Art Unit 1648

Examiner: Wortman, Donna

Atty. Dkt. P 014357/0278772

M#

Client Ref

Appln. Title:

HUMANIZED ANTIBODIES

Sir:

REPLY/AMENDMENT/LETTER

Date: November 5, 2003

This is a reply/amendment/letter in the above-identified application and includes the herewith attachment of same date and subject which is incorporated herein by reference and the signature below is treated as the signature to the attachment in absence of a signature thereto.

FEE REQUIREMENTS FOR CLAIMS AS AMENDED

1. Small Entity claim

- A. ☐ NOT made
B. ☐ Withdrawn
C. ☐ made herewith
D. ☒ made previously

For B & C
See **Required**
Separate Paper
(Pat-256)

Claims remaining after amendment	Highest number previously paid for	Present Extra	Large/Small Entity	Additional Fee	Fee Code Lg/Sm
2. Total Effective Claims	83	**minus 57	26	x \$18/\$9 = + \$234	103/203
3. Independent Claims	3	***minus 3	0	x \$84/\$42 = + \$0	102/202
4. If amendment enters proper multiple dependent claim(s) into this application for first time (leave blank if this is a reissue application)..... add				+ \$280/\$140 = + \$0	104/204
5. Original due Date: August 5, 2003		<input type="checkbox"/> NONE			
6. Petition is hereby made to extend the original due date to cover the date this response is filed for which the requisite fee is attached		(1 mo) \$110/\$55 = (2 mos) \$420/\$210 = (3 mos) \$950/\$475 = (4 mos) \$1480/\$740= (5 mos) \$2010/\$1005	+ \$475		115/215 116/216 117/217 118/218 128/228
7. Enter any previous extension fee paid since above original due date and subtract			- \$0		
8.			Extension Fee		+ \$ 475
9. If Terminal Disclaimer attached, add Rule 20(d) official fee			+ \$110/\$55		+ \$0 148/248
10. If IDS attached requires Official Fee under Rule 97 (c), add			+ \$180		126
or if Rule 97(d) Request add			+ \$180		126
11. After-Final Request Fee per rules 129(a) and 17(r)			+ \$740/370		+ \$0 146/246
12. No. of additional inventions for examination per Rule 129(b)			x \$740/370 ea		+ \$0 149/249
13. Request for Continued Examination (RCE)			+ \$740/370		+ \$0 1179/1279
14. Petition fee for acceptance of colored photographs					+ \$130
15. TOTAL FEE =					\$1,019.00
16. *If the entry in this space is less than entry in next space, the "Present Extra" result is "0".					CHARGE DEPOSIT ACCOUNT
17. **If the "Highest number previously paid for" in this space is less than 20, write "20" in this space.					
18. ***If the "Highest number previously paid for" in this space is less than 3, write "3" in this space.					

Our Deposit Account No. 50-2212

Our Order No. 014357 0278772

C#

M#

CHARGE STATEMENT: The Commissioner is hereby authorized to charge any fee specifically authorized hereafter, or any missing or insufficient fee(s) filed, or asserted to be



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Fang et al.
Serial No. : 09/910,483
Filed : July 19, 2001
Title : Humanized Antibodies

Art Unit : 1648
Examiner : Wortman, D.

Assistant Commissioner of Patents
Washington, DC 20231

RESPONSE TO OFFICE ACTION

In response to the Office Action mailed May 5, 2003, in connection with the above-identified application, the time for responding having been extended to November 5, 2003, by the accompanying fee and petition under 37 C.F.R. §1.136, Applicants respectfully request consideration of the following amendments and remarks:

Amendments to the Specification begin at **page 2** of this paper.

Amendments to the Claims begin at **page 13** of this paper.

Remarks begin at **page 20** of this paper.

Exhibits A and B accompanying this Response are attached following the Conclusion of this paper.

11/13/2003 SSESHE1 00000049 502212 09910483

01 FC:2253 475.00 DA

11/13/2003 SSESHE1 00000049 502212 09910483

02 FC:2202 234.00 DA